These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 2902861)

  • 21. Effects of nilvadipine on the cardiovascular system in experimental animals.
    Ohtsuka M; Koibuchi Y; Sakai S; Tsujioka K; Fujiwara T; Ozaki T; Maeda K; Motoyama I; Horiai H; Ono T
    Arzneimittelforschung; 1988 Nov; 38(11):1605-18. PubMed ID: 3214444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vasodilator and vasoconstrictor responses induced by 5-hydroxytryptamine in the in situ blood autoperfused hindquarters of the anaesthetized rat.
    Calama E; Fernández MM; Morán A; Martín ML; San Román L
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):110-6. PubMed ID: 12122496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. General pharmacological properties of the potent angiotensin converting enzyme inhibitor rentiapril.
    Yamauchi H; Nishimura K; Nakata K; Suda H; Iso T; Shimizu M; Hiramatsu Y
    Arzneimittelforschung; 1987 Feb; 37(2):157-64. PubMed ID: 3034298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation by 5-HT1A receptors of the 5-HT2 receptor-mediated tachykinin-induced contraction of the rat trachea in vitro.
    Germonpré PR; Joos GF; Pauwels RA
    Br J Pharmacol; 1998 Apr; 123(8):1571-8. PubMed ID: 9605563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological studies of mabuterol, a new selective beta 2-stimulant. II: Effects on the cardiovascular system and smooth muscle organs.
    Osada E; Murai T; Ishizaka Y; Sanai K
    Arzneimittelforschung; 1984; 34(11A):1641-51. PubMed ID: 6152157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential vascular alpha1-adrenoceptor blocking properties of an array of 5-HT receptor ligands in the rat.
    Centurión D; Mehotra S; Sánchez-López A; Gupta S; MaassenVanDenBrink A; Villalón CM
    Eur J Pharmacol; 2006 Mar; 535(1-3):234-42. PubMed ID: 16545797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 6-[N,S-dimethyl-N'-cyanothioureidomethyl]-6,11-dihydro-5H- dibenz[b,e]azepine hydrochloride (Fran 12): a histamine and 5-hydroxytryptamine antagonist with pressor properties.
    Law SC; Guyett FJ; King RG; Boura AL; Jackson WR; Hodgson WC
    Arch Int Pharmacodyn Ther; 1992; 317():67-80. PubMed ID: 1360792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. WAY 405, a new silent 5-HT (1A) receptor antagonist with low affinity for vascular alpha (1)-adrenoceptors.
    Villalobos-Molina R; Orozco-Méndez M; López-Guerrero JJ; Gallardo-Ortíz IA
    Auton Autacoid Pharmacol; 2005 Oct; 25(4):185-9. PubMed ID: 16176451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin-induced contraction in porcine coronary artery: use of ergolines to support vascular 5-hydroxytryptamine2-receptor heterogeneity.
    Cushing DJ; Cohen ML
    J Pharmacol Exp Ther; 1993 Jan; 264(1):193-200. PubMed ID: 8423526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. (S)-emopamil, a novel calcium and serotonin antagonist for the treatment of cerebrovascular disorders. 1st communication: pharmacological profile.
    Hofmann HP; Raschack M; Unger L
    Arzneimittelforschung; 1989 Mar; 39(3):304-8. PubMed ID: 2757655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444.
    Ogawa T; Sugidachi A; Tanaka N; Fujimoto K; Asai F
    Eur J Pharmacol; 2002 Dec; 457(2-3):107-14. PubMed ID: 12464356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological activity of ACC-7513, a selective alpha-adrenoceptor and 5-hydroxytryptamine receptor blocking agent.
    Anderson WG; Kam ST
    Br J Pharmacol; 1985 Apr; 84(4):793-800. PubMed ID: 2860940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological characterization of SR 142801: a new non-peptide antagonist of the neurokinin NK-3 receptor.
    Nguyen-Le XK; Nguyen QT; Gobeil F; Pheng LH; Emonds-Alt X; Brelière JC; Regoli D
    Pharmacology; 1996 May; 52(5):283-91. PubMed ID: 8807672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of epiberberine on alpha-adrenoceptors].
    Wang JL; Fang DC
    Yao Xue Xue Bao; 1990; 25(4):289-92. PubMed ID: 2177949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro studies with ICI 169,369, a chemically novel 5-HT antagonist.
    Blackburn TP; Thornber CW; Pearce RJ; Cox B
    Eur J Pharmacol; 1988 Jun; 150(3):247-56. PubMed ID: 3416910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolongation of rat tail bleeding time by ketanserin: mechanisms of action.
    Buczko W; Gambino MC; De Gaetano G
    Eur J Pharmacol; 1984 Aug; 103(3-4):261-8. PubMed ID: 6237923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of DAU 6215, a novel 5-HT3 receptor antagonist, on the cardiovascular system in anaesthetized and pithed rats.
    Malinowska B; Pawlak D; Buczko W
    Agents Actions; 1992 Jul; 36(3-4):230-6. PubMed ID: 1529806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular alpha-adrenergic blocking properties of quinidine.
    Caldwell RW; Elam JT; Mecca TE; Nash CB
    Eur J Pharmacol; 1983 Oct; 94(3-4):185-92. PubMed ID: 6140173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative 5-HT2-receptor antagonist activity of amesergide and its active metabolite 4-hydroxyamesergide in rats and rabbits.
    Cohen ML; Kurz KD; Fuller RW; Calligaro DO
    J Pharm Pharmacol; 1994 Mar; 46(3):226-9. PubMed ID: 8027933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo and in vitro activity of selective 5-hydroxytryptamine2 receptor antagonists.
    Conolan S; Quinn MJ; Taylor DA
    Br J Pharmacol; 1986 Sep; 89(1):129-35. PubMed ID: 3801767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.